Loading...
For most patients with hormone-sensitive metastatic prostate cancer (HSMPC), androgen deprivation therapy (ADT) intensification with docetaxel, abiraterone, enzalutamide, or apalutamide is the standard of care, based on compelling survival benefit demonstrated in phase III studies. The PEACE-1 trial provided evidence of benefit for the addition of abiraterone to ADT plus docetaxel in high-risk patients with metastatic disease at initial presentation (Ann Oncol 2021; 32:suppl 5:S1283).
In the industry-sponsored, international, phase III ARASENS trial, investigators randomized men with HSMPC to receive darolutamide or placebo in addition to ADT plus docetaxel. Randomization was stratified according to the TNM metastasis stage. The primary endp…